Association Between Neutrophil–Lymphocyte Ratio and Frailty: The Chinese Longitudinal Healthy Longevity Survey

Weihao Xu1,2†, Yuanfeng Liang2† and Zhanyi Lin1,2*

1 Department of Cardiology, Guangdong Provincial Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China, 2 Department of Geriatrics, Guangdong Provincial Geriatrics Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China

Background: Inflammation has been reported to play an important role in frailty syndrome. The neutrophil–lymphocyte ratio (NLR) has recently emerged as an informative marker for systematic inflammation. However, few studies have examined the association between NLR and frailty. This study aims to examine the association between NLR and frailty in community-dwelling older adults.

Methods: Community-dwelling older adults aged ≥ 65 years in the 2011 (n = 2,354) and 2014 (n = 2,458) waves of the Chinese Longitudinal Healthy Longevity Survey (CLHLS) were included. Frailty status was determined using the 38-item frailty index (FI) and categorized into “robust” (FI ≤ 0.1), “pre-frail” (0.1 < FI ≤ 0.21), or “frail” (FI > 0.21). NLR was calculated using a derived formula: NLR = (white blood cell–lymphocyte)/lymphocyte.

Results: A total of 3,267 participants were finally included. In cross-sectional analyses, participants with higher NLR levels had increased likelihood of frailty [the 3rd quartile: adjusted odds ratio (OR) = 1.29; 95% confidence interval (CI): 1.02–1.63; the 4th quartile: OR = 1.59; 95% CI: 1.23–2.02] compared with those in the 1st quartile group. During the 3-year follow-up, 164 of the 1,206 participants, robust or pre-frail at baseline, developed frailty, and 197 of the 562 participants, robust at baseline, developed pre-frailty or frailty. Among the robust and pre-frail participants in 2011, after multivariate adjustment, those in the 4th quartile group had a higher frailty incidence than those in the 1st quartile group (OR = 2.06; 95% CI: 1.18–3.59). Among the robust participants in 2011, those in the 4th quartile group also had a higher pre-frailty or frailty incidence than those in the 1st quartile group (OR = 1.95; 95% CI: 1.07–3.55).

Conclusion: Among community-dwelling older adults, higher NLR levels were found to be associated with increased odds of prevalent and incident frailty.

Keywords: inflammatory marker, neutrophil-lymphocyte ratio, frailty, frailty index, old age
INTRODUCTION

Frailty is a common geriatric syndrome characterized by age-associated morphological and physiological changes across multiple systems and organs, resulting in progressive decline of physiological reserve, reduced resilience, and increased vulnerability when exposed to stressors (1). Frail older adults have a significantly increased risk of various adverse outcomes, including falls, cardiovascular disease, hospitalization, nursing home admission, poor surgical outcomes, disability, and death (2–8). Data from epidemiological studies show that the prevalence of frailty is high among community-dwelling older adults: approximately 6, 12, and 25% of persons aged 65–74, 75–84, and 85+ years, respectively (9). Frailty is an emerging health and economic burden for not only individuals and families but also the society.

Understanding the pathophysiological mechanisms of frailty is of great importance for developing prevention and intervention strategies. Collective evidence suggests that chronic inflammation plays an important role in frailty occurrence (10). Previous studies have suggested that higher levels of inflammatory markers are associated with loss of muscle mass and function (lower strength and lower-extremity performance) (11, 12). Furthermore, inflammatory markers are also correlated with accelerated loss of mobility and physical activity (13). In addition, a meta-analysis also showed that frailty and pre-frailty are associated with increased levels of inflammatory markers, particularly CRP and IL-6 (14). The neutrophil–lymphocyte ratio (NLR) has recently emerged as an informative marker for systematic inflammation and has been linked to poor prognosis in several diseases, such as cancers (15), chronic obstructive pulmonary disease (COPD) (16), acute coronary syndrome (ACS) (17), and acute cerebral hemorrhage (ICH) (18). However, few studies have examined NLR as an inflammatory marker of frailty (19, 20). Hou et al. found that a higher NLR level (3rd and 4th quartile of NLR of study sample) is associated with frailty in elderly patients with coronary heart disease (CHD) (19). A study by Nishijima and colleagues also showed an association between frailty and NLR in older adults with cancer (20). However, all previous studies focused on the association between NLR and frailty performed in disease-specific (CHD or cancer) study populations and with small sample sizes, so it is unclear whether the association persists in community-dwelling older adults.

In the present study, we analyzed data from the Chinese Longitudinal Healthy Longevity Survey (CLHLS) to examine the association between NLR and frailty among community-dwelling older adults in China.

METHODS

Study Design and Population

The CLHLS is a nationwide study of community-dwelling older adults aged ≥ 80 years. Face-to-face interviews were used to collect extensive information, including socio-demographic characteristics, psychological characteristics, and physical and cognitive health conditions. This study began enrolling participants in 1998 from 22 of China’s 31 provinces. Follow-up interviews were conducted every 2 years before the third wave (2000 and 2002) and then every 3 years after the third wave (2005, 2008, 2011, and 2014). The study added new samples (adults aged ≥ 80 years in the second wave and adults aged ≥ 65 years in the third and subsequent waves) to replenish participants who had died or were lost to follow-up. In 2011 and 2014, an ancillary study was conducted in eight longevity areas: Laizhou City, Xiayi County, Zhongxiang City, Mayang County, Yongfu County, Sanshui District, Chengmai County, and Rudong County. In this ancillary study, a blood test was added and blood sample was collected voluntarily from study participants with informed consent. Further details about the recruitment strategy and study design of CLHLS have been described elsewhere (21). The current analyses used data from the 2011 and 2014 waves of the CLHLS. In the 2011 wave, 9,679 participants aged 65–114 years were interviewed. Among them, 2,354 participants received blood tests and 2,160 had NLR data. In the 2014 wave, 7,107 participants aged 65–117 years were interviewed. Among them, 2,458 participants received blood tests and 2,401 had NLR data.

Frailty Index

The outcome of interest in this study is frailty, as determined by the frailty index (FI). We constructed the FI following a standard procedure (22). The FI counts health deficits. Health deficits could be defined as symptoms, signs, disabilities, and diseases (18). Health deficits included in the FI must fulfill the following criteria: (1) be associated with health status, (2) show an increase with age and be higher than 1%, (3) not saturate at an early age, and (4) cover several physiological systems. Each health deficit was scored as 0 (absence), 1 (presence), or missing. For each participant, the FI score was calculated by summing the deficits present and dividing by the number of deficits included, and it ranged from 0 to 1. We constructed a 38-item FI (Supplementary Table S1) following an established research using data from CLHLS (23). In our study, participants who had ≥ 30 items were included. After the FI was calculated, all participants were categorized as robust (FI ≤ 0.1), pre-frail (0.1 < FI < 0.21), or frail (FI > 0.21) (24).

Covariates

Covariate variables in this study included age, sex, marital status (married and living with spouse, divorced, widowed, or never married), years of education, current smoking status, current drinking status, current exercise status (Assessed by the question: “Do you exercise regularly now?” Exercise refers to purposeful physical activity, such as walking, playing ball, running, qigong, etc.), and body mass index (BMI).

Neutrophil–Lymphocyte Ratio

Fasting blood samples were collected by trained nurses and tested in a local hospital or a local office of the China Center for Disease Prevention and Control. Blood routine tests only included white blood cell (WBC) count (10^9/L) and lymphocyte count (10^9/L). Thus, the NLR used in this study is a derived NLR (dNLR), calculated as: (WBC – lymphocyte)/lymphocyte (25). NLR levels
TABLE 1 | Characteristics of the community-dwelling older adults of the CLHLS (n = 3,267, according to frailty status).

| Frailty status       | Robust (n = 843) | Pre-frail (n = 1,042) | Frail (n = 1,382) | P-value |
|----------------------|------------------|-----------------------|-------------------|---------|
| **Age [years, median (IQR)]** | 77.0 (70.0, 85.0) | 85.0 (77.0, 93.0) | 95.0 (87.0, 101.0) | <0.001 |
| **Gender (female, %)** | 347 (41.2) | 561 (53.8) | 933 (67.5) | <0.001 |
| **BMI [median (IQR)]** | 21.9 (19.8, 24.2) | 20.9 (18.8, 23.8) | 20.1 (17.9, 22.9) | <0.001 |
| **Marital status (n, %)** | 488 (57.9) | 390 (37.4) | 250 (22.2) | <0.001 |
| Married and living with spouse | 355 (42.1) | 652 (62.6) | 1132 (81.9) | <0.001 |
| Divorced/widowed/never married | 206 (24.4) | 175 (16.8) | 118 (8.5) | <0.001 |
| **Current smoker (n, %)** | 206 (24.4) | 175 (16.8) | 118 (8.5) | <0.001 |
| **Current drinker (n, %)** | 189 (22.4) | 161 (15.5) | 113 (8.2) | <0.001 |
| **Exercise at present (n, %)** | 212 (25.1) | 172 (16.5) | 101 (7.3) | <0.001 |
| **Education years (≥ 5 years, %)** | 320 (38.0) | 179 (17.2) | 156 (11.3) | <0.001 |
| **Comorbidity** | 151 (17.9) | 323 (31.0) | 497 (36.0) | <0.001 |
| **Diabetes** | 13 (1.5) | 36 (3.5) | 132 (9.8) | <0.001 |
| **Heart disease** | 28 (3.3) | 79 (7.6) | 242 (17.5) | <0.001 |
| **Stroke or CVD** | 12 (1.4) | 56 (5.4) | 229 (16.6) | <0.001 |
| **NLR [median (IQR)]** | 2.2 (1.7, 2.9) | 2.1 (1.6, 2.9) | 2.3 (1.7, 3.2) | <0.001 |
| **Frailty index scores [median (IQR)]** | 0.06 (0.03, 0.08) | 0.15 (0.12, 0.18) | 0.31 (0.24, 0.43) | <0.001 |

IQR, interquartile range; BMI, body mass index; CVD, cerebrovascular disease; NLR, neutrophil/lymphocyte ratio.

FIGURE 1 | Flowchart of the study identification process.
were categorized by two ways: (1) quartiles and (2) dichotomous groups ("normal" [≤ 3] vs. "high" [≥ 3] inflammation) (26).

**Statistical Analysis**

To maximize the sample size, all participants had NLR data in the 2011 wave, and participants who were replenished in the 2014 wave and also had NLR data were combined and used in cross-sectional analyses.

Baseline characteristics of the combined sample were reported and compared according to the different frailty statuses (robust, pre-frail, frail). Due to skewed distribution, continuous variables (age, BMI, NLR, and FI) are described as median and interquartile range (IQR) and were compared by the Kruskal-Wallis test. Categorical variables are described as frequencies and were compared by a chi-square test. Cross-sectional association between NLR levels and frailty (robust or pre-frailty vs. frailty) was examined using logistic regression analysis. Prospective associations of NLR levels with a follow-up of (1) frailty (robust or pre-frail participants in the 2011 wave) and (2) pre-frailty or frailty (robust participants in the 2011 wave) were also examined using logistic regression analysis. Three models were built for the logistic regression analysis. In addition to a crude model, model 1 was adjusted for age and sex. Model 2 was additionally adjusted for marital status, education years (≥ 5 years), current smoking status, current drinking status, current exercise status, and BMI.

All analyses were performed using the SPSS 26.0 for Windows (SPSS Inc., Chicago, IL). P < 0.05 were considered statistically significant.

**RESULTS**

**Characteristics of Study Population**

Figure 1 shows the details of study selection process. Of the 3,267 participants, 843 were robust (25.8%), 1,042 were pre-frail (31.9%), and 1,382 were frail (42.3%). The characteristics of included participants are presented in Table 1. The median age was 87.0 years (IQR, 77.0–98.0 years). Females accounted for 56.4% of the participants. Age, BMI, NLR, proportion of females, marital status, current smoking status, current drinking status, education level, current exercise status and comorbidity [hypertension, diabetes, heart disease and stroke or cerebrovascular disease (CVD)] were significantly different among the three groups.

**Cross-Sectional Association Between NLR Levels and Frailty**

In the multivariable adjusted model, participants in the highest two quartiles of NLR groups had significantly greater odds of frailty than those in the lowest quartile (OR = 1.29, 95% CI: 1.02–1.63 for the 3rd quartile, and OR = 1.59, 95% CI: 1.23–2.02 for the 4th quartile). There was a significant trend of increasing cumulative odds of frailty with higher NLR level (P for trend < 0.001). When NLR was categorized into dichotomous groups, participants in "high" inflammation state (NLR ≥ 3) had a 46% higher likelihood of frailty (OR = 1.46, 95% CI: 1.21–1.78) than those in normal inflammation state (NLR < 3) (Table 2).

**Prospective Association Between NLR Levels and Frailty**

During the follow-up period, 164 of the 1,206 robust or pre-frail participants developed frailty. After full adjustment for confounders, participants in the 4th quartile NLR group were associated with a more than 2-fold greater likelihood of incidence of frailty than participants in the 1st quartile group. When NLR was categorized into dichotomous groups, participants in “high” inflammation state (NLR ≥ 3) had an 84% higher likelihood of incidence of frailty than those in normal inflammation state (NLR < 3) (Table 3).

During the follow-up period, 197 of the 562 robust participants developed pre-frailty or frailty. After multivariable adjustment, participants in the 4th quartile NLR group had nearly double the risk of incident pre-frailty or frailty that those in the 1st quartile group. When NLR was categorized into dichotomous groups, participants whose NLR ≥ 3 at baseline had more than 2-fold greater likelihood of incident pre-frailty or frailty than those had NLR < 3 (Table 4).

**DISCUSSION**

In this large prospective cohort study of more than 3,000 community-dwelling older adults, we found that a higher NLR level was associated with increased odds of prevalent and incident frailty.

Based on our literature search, few studies have investigated the association between NLR and frailty. Nishijima and colleagues performed a cross-sectional study of 133 elderly patients with cancer to examine the association between NLR and frailty. They used the 36-item Carolina Frailty Index to assess frailty status and reported that patients in the highest tertile NLR group had nearly 4-fold increased odds of frailty (20). Another cross-sectional study by Hou et al. was conducted on 345 elderly patients with coronary heart disease to explore the relationship between NLR and frailty. This study used

---

**Table 2** Cross-sectional association of NLR with frailty in community-dwelling older adults of the CLHLS (n = 3,267).

| NLR group 1 | Crude model | Model 1a | Model 2b |
|-------------|-------------|----------|----------|
| Quartile 1  | 1.00        | 1.00     | 1.00     |
| Quartile 2  | 0.95 (0.78–1.16) | 1.07 (0.85–1.34) | 0.97 (0.76–1.23) |
| Quartile 3  | 1.14 (0.94–1.38) | 1.34 (1.08–1.67)** | 1.29 (1.02–1.63) * |
| Quartile 4  | 1.56 (1.28–1.90)** | 1.77 (1.41–2.22)** | 1.59 (1.23–2.02)** |

**P-value for trend**< 0.001.< 0.001.< 0.001

| NLR group 2 | Normal (≤3) | Abnormal (≥3) |
|-------------|-------------|---------------|
| Crude model | 1.00        | 1.00          |
| Model 1a    | 1.00        | 1.00          |
| Model 2b    | 1.00        | 1.00          |

NLR, neutrophil lymphocyte ratio.  
*Adjusted for age and sex.  
**Adjusted for age, sex, marital status, education years (≥5 years), current smoking status, current drinking status, current exercise status and body mass index.  
**P < 0.05; **P < 0.01; ***P < 0.001.
TABLE 3 | Prospective association of NLR with incidence of frailty in robust or pre-frail (n = 1,206) community-dwelling older adults of the CLHLS study cohort.

| NLR group 1 | Crude model | Model 1* | Model 2b |
|-------------|-------------|----------|----------|
| Quartile 1  | 1.00        | 1.00     | 1.00     |
| Quartile 2  | 1.28 (0.78–2.11) | 1.39 (0.80–2.41) | 1.31 (0.75–2.28) |
| Quartile 3  | 1.33 (0.80–2.21) | 1.61 (0.92–2.82) | 1.53 (0.87–2.70) |
| Quartile 4  | 1.56 (0.96–2.55) | 2.09 (1.21–3.62)** | 2.06 (1.18–3.59)* |
| P-value for trend | 0.082 | 0.008 | 0.009 |

TABLE 4 | Prospective relationship between NLR and incidence of pre-frailty or frailty in robust (n = 562) community-dwelling older adults of the CLHLS.

| NLR group 1 | Crude model | Model 1* | Model 2b |
|-------------|-------------|----------|----------|
| Quartile 1  | 1.00        | 1.00     | 1.00     |
| Quartile 2  | 0.96 (0.56–1.65) | 0.92 (0.52–1.63) | 0.93 (0.52–1.65) |
| Quartile 3  | 1.18 (0.68–2.07) | 1.24 (0.69–2.22) | 1.20 (0.66–2.17) |
| Quartile 4  | 1.86 (1.07–3.42)* | 1.99 (1.10–3.60)* | 1.95 (1.07–3.55)* |
| P-value for trend | 0.016 | 0.009 | 0.014 |

NLR, neutrophil/lymphocyte ratio.
*Adjusted for age and sex.
**Adjusted for age, sex, marital status, education years (≥5 years), current smoking status, current drinking status, current exercise status and body mass index.

*P < 0.05, **P < 0.01.

the Fried frailty phenotype to define frailty and showed that participants in the 3rd and 4th quartile NLR groups had higher odds for frailty (OR = 2.53 and 2.89, respectively) (19). Both these studies had limitations, including cross-sectional design, small sample size, and disease-specific study populations, which limited the generalization of study findings, but they indicated a possible association between NLR and frailty. Our study, based on a large sample of community-dwelling older adults, further demonstrates the association between NLR and frailty by both cross-sectional and prospective analyses.

Although limited studies have focused on the NLR and frailty, there is much evidence exploring the association between NLR and sarcopenia, which is a common geriatric syndrome and is significantly associated with frailty. A recent study by Abete et al. enrolled 1,535 overweight/obese participants and found that NLR is negatively associated with sarcopenic index, as assessed using dual-energy X-ray absorptiometry scanning (27). Studies conducted on patients with cancer have shown that increasing NLR is associated with sarcopenia in a dose-response manner (26). Considering that sarcopenia is a strong risk factor for frailty, the above evidence might indirectly indicate the association between NLR and frailty.

Inflammation has been widely considered to be associated with frailty. Most frail older adults have chronic inflammation, especially those with comorbid sarcopenia (28, 29). Previous research has found that inflammation is associated with decreased synthesis and activity of insulin-like growth factor I (IGF1), which plays an essential role in muscle regeneration and maintenance of muscle integrity (30). There is also evidence showing that IGF1-mediated anabolism can be inhibited by IL-1α, IL-6, and that both TNF inhibitors in vitro and IL-6 can reduce the production of IGF1 and IGF-binding protein 3 (31). In addition, observational studies have reported that high IL-6 levels and low IGF1 levels synergistically correlate with lower muscle strength and power, which is the main clinical manifestation of frailty (32). Furthermore, studies have shown that NLR is significantly correlated with IL-6, CRP, and TNF-α (33–35). However, the mechanism underlying the association between NLR and frailty is unclear. We speculate that a higher level of NLR is secondary to an existing high systemic inflammation level, and NLR might serve as an indirect marker of inflammation. This hypothesis needs to be verified in further studies.

To the best of our knowledge, our study, for the first time, examined the prospective association between NLR and frailty. Our results point toward the possible clinical application of NLR since the NLR data can be easily available from a routine blood test. More attention should be paid to community-dwelling older adults or elderly patients with higher NLR level to take early preventive measures to reduce the occurrence of frailty as well as the adverse outcomes associated with frailty. It should be noted that the optimal cut-off point of NLR is not yet established. Although we found the cut-off value of ≥3 for NLR, which was recommended by a previous study (26), was able to predict future pre-frailty and frailty, more longitudinal studies are still warranted to further explore the best cut-off value for NLR in older adults. Strengths or our study also include a large sample size and nationally representative study population. We also acknowledge several limitations of this study. First, we could only use the FI to define the frailty status of participants in the CLHLS cohort study. Considering that the association between NLR and frailty might be involved in the mechanism of frailty, the Fried frailty phenotype should be the ideal assessment tool for frailty under this circumstance. Future studies using the Fried frailty phenotype to define frailty are warranted to further investigate the association between NLR and frailty. Second, the analytic sample for the prospective associations between NLR and frailty was relatively small due to follow-up loss and death. Third, our study was conducted among community-dwelling older adults, and the study results may not generalize to elderly patients, especially those with inflammatory diseases. Finally, residual confounding factors (polypharmacy, sarcopenia, depression, fruit/vegetable/protein consumption, etc.) for frailty may still be present, although we adjusted for several confounders.
CONCLUSIONS AND IMPLICATIONS

In summary, the present study confirms the association between NLR and frailty in community-dwelling older adults. The NLR relies on information obtained from a simple blood test, which is available in epidemiological studies; it can be administered in various care and clinical settings; and serves as a risk factor for frailty.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Peking University and Duke University. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

WX wrote and participated in all aspects of this research, including the field investigation. YL analyzed the data and interpreted the results. ZL designed this research. All authors reviewed the manuscript and agree to be accountable for the content of the work.

FUNDING

This study was supported by National Key R&D Program of China (2018YFC200301).

ACKNOWLEDGMENTS

We are grateful to those who offered any help in this article.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmed.2021.783077/full#supplementary-material

REFERENCES

1. Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K. Frailty in elderly people. Lancet. (2013) 381:752–62. doi: 10.1016/S0140-6736(12)62167-9
2. Bromfield SG, Ngameni CA, Colantonio LD, Bowling CB, Shimbo D, Reynolds K, et al. Blood pressure, antihypertensive polypharmacy, frailty, and risk for serious fall injuries among older treated adults with hypertension. Hypertension. (2017) 70:259–66. doi: 10.1161/HYPERTENSIONAHA.116.09390
3. Sergi G, Veronese N, Fontana L, De Rui M, Bolzetta F, Zambon S, et al. Pre-frailty and risk of cardiovascular disease in elderly men and women: the Pro. VA study. J Am Coll Cardiol. (2015) 65:976–83. doi: 10.1016/j.jacc.2014.12.040
4. Son YJ, Shim DK, Seo EK, Won MH. Gender differences in the impact of frailty on 90-day hospital readmission in heart failure patients: a retrospective cohort study. Eur J Cardiovasc Nurs. (2021). doi: 10.1093/ejcn/nzaa028
5. Ferrante LE, Pisani MA, Murphy TE, Gahbauer EA, Leo-Summers LS, Gill TM. The association of frailty with post-ictus disability, nursing home admission, and mortality: a longitudinal study. Chest. (2018) 153:1378–86. doi: 10.1016/j.chest.2018.03.007
6. Veronesi F, Borsari V, Martini L, Visani A, Gasbarrini A, Brodano GB, et al. The impact of frailty on spine surgery: systematic review on 10 years clinical studies. Aging Dis. (2021) 12:625–45. doi: 10.14336/AD.2020.0904
7. Doi T, Tsutsumimoto K, Ishii H, Nakakubo S, Kurita S, Shimada H. Frailty and driving status associated with disability: a 24-month follow-up longitudinal study. BMJ Open. (2021) 11:e042468. doi: 10.1136/bmjopen-2020-042468
8. Middleton R, Poveda JL, Orfila Pernas F, Martinez Laguna D, Diez Perez A, Nogues X, et al. Mortality, falls and fracture risk are positively associated with frailty: a SIDIAP cohort study of 890,000 patients. J Gerontol A Biol Sci Med Sci. (2021) gla102. doi: 10.1093/gerona/gla102
9. Kong LN Lyu Q, Yao HY, Yang L, Chen SZ. Prevalence and risk factors for frailty among community-dwelling older people in China: a systematic review and meta-analysis. J Nutr Health Aging. (2019) 23:442–50. doi: 10.1007/s12603-017-1179-9
10. Ferrucci L, Fabbri E. Inflammaging: chronic inflammation in ageing, cardiovascular disease, and frailty. Nat Rev Cardiol. (2018) 15:505–22. doi: 10.1038/s41591-018-0064-2
11. Ferrucci L, Penninx BW, Volpato S, Harris TB, Bandeen-Roche K, Balfour J, et al. Change in muscle strength explains accelerated decline of physical function in older women with high interleukin-6 serum levels. J Am Geriatr Soc. (2002) 50:1947–54. doi: 10.1046/j.1532-5415.2002.500605.x
12. Visser M, Pahor M, Taaffe DR, Goodpaster BH, Simonsick EM, Newman AB, et al. Relationship of interleukin-6 and tumor necrosis factor-alpha with muscle mass and muscle strength in elderly men and women: the Health ABC Study. J Gerontol A Biol Sci Med Sci. (2002) 57:M326–332. doi: 10.1093/gerona/57.5.M326
13. Cesari M, Penninx BW, Pahor M, Lauretani F, Corsi AM, Rhys Williams G, et al. Inflammatory markers and physical performance in older persons: the InCHIANTI study. J Gerontol A Biol Sci Med Sci. (2004) 59:242–8. doi: 10.1093/gerona/59.3.M242
14. Soyal P, Stubbs B, Lucato P, Luchini C, Solmi M, Peluso R, et al. Inflammation and frailty in the elderly: a systematic review and meta-analysis. Ageing Res Rev. (2016) 31:1–8. doi: 10.1016/j.arr.2016.08.006
15. Guthrie GJ, Charles KA, Roxburgh CS, Horgan PG, McMillan DC, Clarke SJ. The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Crit Rev Oncol Hematol. (2013) 88:218–30. doi: 10.1016/j.critrevonc.2013.03.010
16. Paliogiannis P, Fois AG, Sotgia S, Mangoni AA, Zinelli E, Pirina P, et al. Neutrophil to lymphocyte ratio and clinical outcomes in COPD: recent evidence and future perspectives. Eur Respir Rev. (2018) 27:170113. doi: 10.1183/16000617.0113-2017
17. Zhang S, Diao J, Qi C, Jin J, Li G, Gao X, et al. Predictive value of neutrophil to lymphocyte ratio in patients with acute ST segment elevation myocardial infarction after percutaneous coronary intervention: a meta-analysis. BMC Cardiovasc Disord. (2018) 18:75. doi: 10.1186/s12872-018-0812-6
18. Lattanzi S, Brigo F, Trinka E, Cagnetti C, Di Napoli M, Silvestrini M. Neutrophil-to-lymphocyte ratio in acute cerebral hemorrhage: a system review. Transl Stroke Res. (2019) 10:137–45. doi: 10.1007/s12975-018-0649-4
19. Hou P, Xue HP, Mao XE Li YN, Wu LF, Liu YB. Inflammation markers are associated with frailty in elderly patients with coronary heart disease. Aging. (2018) 10:2636–45. doi: 10.18632/aging.101575
20. Nishijima TF, Deal AM, Williams GR, Guerard EJ, Nyrop KA, Muss HB. Frailty and inflammatory markers in older adults with cancer. Aging. (2017) 9:650–64. doi: 10.18632/aging.101162
21. Dupre ME, Gu D, Warner DF Yi Z. Frailty and type of death among older adults in China: prospective cohort study. BMJ. (2009) 338:b1175. doi: 10.1136/bmj.b1175
22. Searle SD, Mitnitski A, Rockwood K. A standard procedure for creating a frailty index. *BMC Geriatr.* (2008) 8:24. doi: 10.1186/1471-2318-8-24

23. Bennett S, Song X, Mitnitski A, Rockwood K. A limit to frailty in very old, community-dwelling people: a secondary analysis of the Chinese longitudinal health and longevity study. *Age Ageing.* (2013) 42:372–7. doi: 10.1093/ageing/afs180

24. Malmsjö TK, Miller DK, Morley JE. A comparison of four frailty models. *J Am Geriatr Soc.* (2014) 62:721–6. doi: 10.1111/jgs.12735

25. Capone M, Giannarelli D, Mallardo D, Madonna G, Festeño L, Grimaldi AM, et al. Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab. *J Immunother Cancer.* (2018) 6:74. doi: 10.1186/s40428-018-0383-1

26. Abete I, Konieczna J, Zulet MA, Galmés-Panades AM, Ibero-Baraibar I, Babio N, et al. Association of lifestyle factors and inflammation with sarcopenic obesity: data from the PREDIMED-Plus trial. *J Cachexia Sarcopenia Muscle.* (2019) 10:974–84. doi: 10.1002/jcsm.12442

27. Feliciano EMC, Kroenke CH, Meyerhardt JA, Prado CM, Bradshaw PT, Kwan ML, et al. Association of systemic inflammation and sarcopenia with survival in nonmetastatic colorectal cancer: results from the C SCAN5 Study. *JAMA Oncol.* (2017) 3:e172319. doi: 10.1001/jamaoncol.2017.2319

28. Walston J, McBurnie MA, Newman A, Tracy RP, Kop WJ, Hirsch CH, et al. Frailty and activation of the inflammation and coagulation systems with and without clinical comorbidities: results from the cardiovascular health study. *Arch Intern Med.* (2002) 162:2333–41. doi: 10.1001/archinte.162.20.2333

29. Hubbard RE, O’Mahony MS, Savva GM, Calver BL, Woodhouse KW. Inflammation and frailty measures in older people. *J Cell Mol Med.* (2009) 13:3103–9. doi: 10.1111/j.1582-4934.2009.00733.x

30. Vassilakos G, Barton ER. Insulin-like growth factor I regulation and its actions in skeletal muscle. *Compr Physiol.* (2018) 9:413–38. doi: 10.1002/cphy.c180010

31. Lazarus DD, Moldawer LL, Lowry SF. Insulin-like growth factor-1 activity is inhibited by interleukin-1 alpha, tumor necrosis factor-alpha, and interleukin-6. *Lymphokine Cytokine Res.* (1993) 12:219–23.